Abstract
Progression from actinic keratosis (AK) and Bowen's disease (BD) to invasive disease involves a complex cascade of events. The preparation of diclofenac 3% gel (Solaraze™; Shire Pharmaceuticals) has been shown to be efficacious and well tolerated in AK. The inhibition of the COX enzymes results in a decrease in downstream by-products of arachidonic acid metabolism. These metabolites have been shown to play a pivotal role in promoting epithelial tumour growth. Given its mechanism of action, we hypothosize that diclofenac 3% gel may have potential to halt the progression of actinic keratoses (AKs) in the setting of field cancerisation and BD. We report a series of five patients with BD, all treated with diclofenac 3% gel with clinical and histological clearance.
Original language | English (US) |
---|---|
Pages (from-to) | 53-56 |
Number of pages | 4 |
Journal | British Journal of Dermatology |
Volume | 156 |
Issue number | SUPPL. 3 |
DOIs | |
State | Published - May 2007 |
Externally published | Yes |
Keywords
- Actinic keratosis
- Bowen's disease
- Diclofenac 3% gel
ASJC Scopus subject areas
- Dermatology